| Literature DB >> 30550791 |
James T Neal1, Xingnan Li1, Junjie Zhu2, Valeria Giangarra3, Caitlin L Grzeskowiak1, Jihang Ju1, Iris H Liu1, Shin-Heng Chiou4, Ameen A Salahudeen1, Amber R Smith1, Brian C Deutsch1, Lillian Liao1, Allison J Zemek5, Fan Zhao4, Kasper Karlsson1, Liora M Schultz6, Thomas J Metzner7, Lincoln D Nadauld1, Yuen-Yi Tseng8, Sahar Alkhairy8, Coyin Oh8, Paula Keskula8, Daniel Mendoza-Villanueva9, Francisco M De La Vega9, Pamela L Kunz6, Joseph C Liao7, John T Leppert7, John B Sunwoo10, Chiara Sabatti11, Jesse S Boehm8, William C Hahn12, Grace X Y Zheng3, Mark M Davis13, Calvin J Kuo14.
Abstract
In vitro cancer cultures, including three-dimensional organoids, typically contain exclusively neoplastic epithelium but require artificial reconstitution to recapitulate the tumor microenvironment (TME). The co-culture of primary tumor epithelia with endogenous, syngeneic tumor-infiltrating lymphocytes (TILs) as a cohesive unit has been particularly elusive. Here, an air-liquid interface (ALI) method propagated patient-derived organoids (PDOs) from >100 human biopsies or mouse tumors in syngeneic immunocompetent hosts as tumor epithelia with native embedded immune cells (T, B, NK, macrophages). Robust droplet-based, single-cell simultaneous determination of gene expression and immune repertoire indicated that PDO TILs accurately preserved the original tumor T cell receptor (TCR) spectrum. Crucially, human and murine PDOs successfully modeled immune checkpoint blockade (ICB) with anti-PD-1- and/or anti-PD-L1 expanding and activating tumor antigen-specific TILs and eliciting tumor cytotoxicity. Organoid-based propagation of primary tumor epithelium en bloc with endogenous immune stroma should enable immuno-oncology investigations within the TME and facilitate personalized immunotherapy testing.Entities:
Keywords: PD-1; PDO; T cell receptor; TCR; cancer; checkpoint inhibitor; immunotherapy; organoid; single-cell RNA-seq; tumor-infiltrating lymphocyte
Mesh:
Substances:
Year: 2018 PMID: 30550791 PMCID: PMC6656687 DOI: 10.1016/j.cell.2018.11.021
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 66.850